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Background: Long-term corticosteroid use may increase cataract risk. The Lens Opacities Clas-
sification System (LOCS) III ranked lens opacities as Class 1: 0.5e0.9 unit; Class 2: 1.0
e1.4 units; or Class 3: 1.5 units in clinical trials of combined mometasone furoate and formo-
terol (MF/F) administered by metered-dose inhaler (MDI). We examined retrospectively shifts
in lenticular opacity in patients with chronic obstructive pulmonary disease (COPD) or asthma.
Methods: We analyzed pooled LOCS III data from two COPD studies and separately analyzed
LOCS III data from an asthma study. COPD subjects were randomized to twice daily MF/F
200/10 mg, MF/F 400/10 mg, MF 400 mg, F 10 mg, and placebo; asthma subjects were random-
ized to MF/F 200/10 mg, MF/F 400/10 mg, fluticasone propionate/salmeterol (FP/S) 250/50 mg,
and FP/S 500/50 mg. Lenticular opacity changes were analyzed post hoc for proportions of sub-
jects with LOCS III grade increases 0.5, 1.0, or 1.5 units at weeks 26 and 52.
Results: Proportions of subjects in the COPD studies with Class 1 (0.5 unit), 2 (1.0 unit), or 3
(1.5 units) increases in LOCS III at week 26 (NZ 1675) ranged from 15.5 to 18.6%, 3.3e6.0%,
and 0.9e2.2%, respectively. At week 52 (N Z 1085), proportions of active-treated subjects
with Class 1, 2, or 3 increases in LOCS III ranged from 26.6 to 28.9%, 6.3e10.7%, and 2.6
e5.9%, respectively. Treatment differences in lenticular shifts were generally small and
nonsignificant in the asthma study.4966 1661; fax: þ54 11 4961 5495.
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BDP beclomethasone dipro
C cortical [lens opacity]
CIC ciclesonide
COPD chronic obstructive pu
F formoterol
FP/S fluticasone propionate
ICS inhaled corticosteroid
LABA long-acting b2-agonists
LOCS Lens Opacities Classifi
MDI metered-dose inhaler
MF mometasone furoate
MF/F mometasone furoate a
combination
N nuclear [lens opacity]
NC nuclear color
NO nuclear opalescence
P posterior subcapsularConclusion: No clinically relevant trends were observed in the LOCS III assessment of lenticular
shifts during treatment of COPD and asthma patients, although further study may be needed to
confirm the findings presented here. In these trials, MF/F effects on lens opacity were not
observed. (Clinicaltrials.gov numbers: NCT00383435, NCT00383721, and NCT00379288.)
ª 2014 Elsevier Ltd. All rights reserved.pionate
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Chronic obstructive pulmonary disease (COPD) and asthma
are common, and COPD is a growing concern because of its
increasing incidence in the general population. Many pa-
tients with COPD or persistent asthma use daily therapy
with fixed-dose combinations of inhaled corticosteroids
(ICS) and long-acting b2-agonists (LABA). ICS/LABA combi-
nations are generally considered safe and effective for
treatment of asthma and COPD, although their possible
systemic effects on bone, cortisol metabolism, and the eyes
(in particular posterior subcapsular cataract) are important
points of concern.
Cataracts are a growing problem, and in 2010 were
estimated to be responsible for 51% of world blindness [1].
It is difficult to assess the expected background rates for
cataracts in the general population because cataract eti-
ology is multifactorial, and is affected by personal, nutri-
tional, medical, and other characteristics [2]. A U.S.
nationwide survey of patients with COPD identified cata-
racts as a common comorbidity (31e32%), but ICS use was
not assessed [3].
The Longitudinal Study of Cataract (LSC) evaluated
changes over time in nuclear (N), cortical (C), and posterior
subcapsular (P) lens opacities, and assessed risk factors for
cataract growth among subjects with a median age of 65
years [4]. The possible risk factors were categorized as
demographic/personal characteristics (eg, age, race),
medical history (eg, smoking, medication use), and other
factors (eg, family history of cataract). In subjects who didnot have P opacities at baseline, the LSC found white race,
gout medications, and current smoking to be the strongest
risk factors for cataract growth. These results are consis-
tent with the multifactorial etiology of lens opacification
[4]. The LSC study is noteworthy because it used the Lens
Opacities Classification System (LOCS) III, a validated
method for lenticular assessment [5].
The LOCS III is used to categorize changes in NO (nuclear
opalescence, a proxy for nuclear opacity), C (cortical) and
P (posterior subcapsular) lens opacity, as well as changes in
nuclear color (NC). It has improvements over the earlier
LOCS II system, including decimalized rather than integer
grading to allow more precise identification of the severity
of the lenticular opacity, and expanded NO and P scales to
facilitate early detection of cataracts in these portions of
the lens [5]. Ophthalmologists grade lens opacity using 6
slit-lamp images for NO and NC, as well as 5 retro-
illumination images each for C and P opacity. The LOCS III
scale for all lens portions and NC ranges from 0.1 (clear or
colorless) to 5.9 (very opaque) for C and P opacities and 6.9
(very opaque or brunescent) for NO opacity and NC [5].
Epidemiologic studies in adults and elderly patients have
found long-term exposure to ICS to be associated with
increased cataract risk. [6e8] Prospective, randomized,
controlled clinical studies can further elucidate the effects
of ICS treatment on lens opacity, and studies with well-
matched treatment groups can provide results not
confounded by background cataract risk factors. A clinical
study can also provide information on treatment-associated
changes in a relatively short period.
Clinical study findings on lenticular shifts measured by
LOCS III associated with the ICS monotherapies ciclesonide
(CIC) and beclomethasone dipropionate (BDP), both
administered by metered dose inhaler (MDI) in patients
with asthma, have been published [9]. That study ranked
positive lenticular shifts into different classes according to
the degree of NO, C, and P opacity, and its primary
endpoint was the event of a positive Class I shift in the LOCS
III score of 0.5 for NO, 0.8 for C, and 0.5 for P. The
non-inferiority analysis found CIC and BDP treatment
groups to have small, similar changes from baseline in LOCS
III scores [9]. However, the lack of a placebo control group
is a limitation of the CIC vs BDP trial. Lenticular effects as
measured by LOCS III associated with the use of the com-
bination MDI treatment mometasone furoate/formoterol
(MF/F) have been investigated in three studies: two in
COPD and one in asthma. The COPD studies were placebo-
controlled and the asthma study was active (combined
fluticasone propionate/salmeterol [FP/S])-controlled. In
those trials, changes 1.0 unit in LOCS III were monitored
as secondary safety endpoints and the findings were re-
ported elsewhere [10e12].
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gross LOCS III changes greater than or equal to one, a more
detailed examination of LOCS III grading of lenticular shifts
with MF/F-MDI treatment in patients with COPD or asthma
is of interest. We conducted post hoc analyses of LOCS III
scores to characterize shifts in lenticular opacity in patients
with COPD or asthma treated with MF/F-MDI or comparative
agents. The comparative agents were MF-MDI, formoterol
[F]-MDI, and placebo in the COPD studies, and FP/S-MDI in
the asthma study.Methods
We performed a post hoc analysis of pooled data from LOCS
III assessments in two COPD studies of MF/F-MDI
(NCT00383435; NCT00383721) and a separate analysis of
data from LOCS III assessments in an asthma safety study of
MF/F-MDI (NCT00379288). These studies were funded by
Merck Sharp & Dohme Corp., Whitehouse Station, NJ USA.
The COPD studies were randomized, double-blinded, and
placebo-controlled multicenter trials. All treatments were
administered twice daily via an MDI. The two COPD studies
involved a combined total of 2251 subjects randomized to
MF/F 200/10 mg, MF/F 400/10 mg, MF 400 mg, F 10 mg, and
placebo. However, only those subjects with both a baseline
and a post-baseline LOCS III assessment were considered in
the post hoc analysis (N Z 1675 at week 26; N Z 1085 at
week 52).
Co-primary endpoints in the COPD studies were changes
from baseline in the morning (AM) pre-dose (trough) forced
expiratory volume in one second (FEV1), and the 12-h AUC of
the post-dose serial FEV1, both at week 13 using last-
observation-carried-forward (LOCF). Both studies had a 26-
week treatment period followed by a 26-week safety
extension, in which 75% of active-treated subjects partici-
pated and continued treatment. The asthma study was a
randomized, active-controlled, investigator-blinded multi-
center trial, which involved 404 subjects randomized to MF/
F 200/10 mg, MF/F 400/10 mg, FP/S 250/50 mg and FP/S 500/
50 mg. However, only subjects with LOCS III evaluations at
baseline and post-baseline were considered for the post hoc
analysis (NZ 299 atweek 26;NZ 355 atweek 52). This was a
52-week safety study, and the primary objective was to
determine the number and proportion of randomized sub-
jectswho reported adverse events. Themethods of the three
studies have been published in detail previously [10e12].
The study protocols were approved by institutional re-
view boards and independent ethics committees at the
study centers, and all patients provided written informed
consent prior to any study-related activity. No protocol
approvals or subject consent were necessary for this
retrospective post hoc analysis. Subject inclusion and
exclusion criteria are described in the primary publications.
Briefly, the COPD studies enrolled subjects aged 40 years
with a history of moderate to very severe COPD, and the
asthma study enrolled subjects aged 12 years with a 12-
month history of persistent asthma. Criteria for exclusion
from participation in the COPD and asthma studies included
history of and/or presence at screening of intraocular
pressure in either eye 22 mm Hg and/or glaucoma. Sub-
jects with bilateral cataract extractions were excludedfrom the COPD studies. In addition, the COPD and asthma
studies excluded subjects who had one or more of the
following LOCS III grades at screening: N  3.0; nuclear
color (NC) 3.0; C  2.0; or P  0.5.
In the two COPD studies, LOCS III assessments were done
at screening, week 26, and week 52 for active-treatment
extension subjects; placebo subjects discontinued at week
26 and did not enter the safety extension. Two post-
screening LOCS III evaluations were scheduled (at weeks
26 and 52), but subjects could have had repeat evaluations
within a visit window, or one evaluation if they were not
selected to continue past the week 26 visit. The LOCS III
assessments were at screening and week 26 only for pla-
cebo subjects and non-extenders. In the asthma study,
LOCS III assessments were done at screening, week 26, and
week 52.
Ocular assessments
Applanation tonometry and a slit lamp examination with
dilation were performed at screening, week 26, and week
52. The LOCS III grading system was used in conjunction
with the ophthalmic examination for evaluating increases
from baseline in lens opacification and cataract formation
at each of these visits with ophthalmologists trained and
certified in the LOCS III grading system. The study protocols
called for LOCS III grading with dilated pupils. The same
ophthalmologist performed all the assessments and LOCS III
grading in any given subject.
LOCS III grades are specific for one class of lens opaci-
fication: NO exclusively for nuclear cataract, C exclusively
for cortical cataract, and P exclusively for posterior sub-
capsular cataract. There is no combination of these LOCS III
grades; they stand on their own as a measure of the
severity of that specific cataract. Therefore, decimal
grades using 0.1-unit intervals were assigned individually to
the NO, C, and P opacities for each subject. Ophthalmolo-
gists classified lenticular shift data as changes in NO, C,
and/or P opacity, ranked as Class 1: 0.5e0.9 unit; Class 2:
1.0e1.4 units; or Class 3: 1.5 units. An event was assigned
to a subject with at least one qualifying change from the
screening score in the left, right or both eyes in NO, C, or P
opacification at any visit. Larger apparent worsening of
lenticular opacity (eg Class 3 shifts) are more likely to
indicate actual clinical worsening than are smaller changes
(eg, Class 1 shifts), which may be due to aging and grader
variability.
Statistical analysis
We performed analysis of LOCS III grade increases of 0.5,
1.0, or 1.5 units for each scheduled evaluation at weeks
26 and 52. The sample size was adjusted to include only
those subjects with a baseline LOCS evaluation, in whom
there is potential to detect a shift from baseline to week 26
or to week 52. Treatment difference confidence intervals
and p-values for the proportion of subjects with an increase
are based on the Meittinen and Nurminen (MN) method
[13]. P-values are reported if they meet the threshold for
statistical significance (p  0.05). However, given the post
hoc nature of the analysis, with multiple observations
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significant p-values are descriptive in nature, and are not
adjusted for multiplicity.
Results
Populations analyzed
A total of 1956 COPD patients and 381 asthma patients had
a baseline LOCS evaluation and at least one post baseline
LOCS evaluation and therefore were included in the ana-
lyses of lenticular shifts. Subjects in the COPD studies had
mean age of about 60 years, and over 40% of subjects were
current smokers. Subjects in the asthma study had mean
age of about 36 years, and <15% of subjects with asthma
were current smokers.
Sample sizes varied across the individual weeks 26 and
52 evaluations due to the amount of data collected at those
visits. Exposure-adjusted (up to 52 weeks) event rates are
stated in units of patient-years to adjust for varying dura-
tion of exposure across treatments. In the COPD studies,
each active treatment group had >300 patient-years of
exposure, whereas placebo group had <200 patient-years
of exposure (Fig. 1). Placebo subjects did not continue in
the study after week 26, contributing to the reduced
exposure compared to the active treatment groups. The
MF/F treatment groups in the asthma study had >115
patient-years of exposure, compared with <64 patient-
years of exposure in the FP/S groups. Increased exposure
of the MF/F treatment compared to FP/S is attributed to
the 2:1 randomization in the MF/F and FP/S groups,
respectively (Table 1).
LOCS III scores in COPD
Mean data at week 26 show that between 15.5% and 17.5%
of subjects in the active treatment groups and 18.6% ofFigure 1 Patient-years of exposure in the pooled COPD studies. B
F, formoterol; LOCS, lens opacity classification system; MDI, metesubjects in the placebo group had events with Class 1
(0.5 unit) increases in NO, C, and/or P scores over the
respective treatment periods. Class 2 (1.0 unit) increases
in lenticular opacity occurred in 3.3%e4.6% of active-
treated subjects, whereas 6.0% of placebo subjects had a
Class 2 increase. Class 3 (1.5 units) increases occurred in
0.9%e1.2% of active-treated subjects and in 2.2% of pla-
cebo subjects (Table 2). At the week 52 evaluation that
does not include placebo subjects, between 26.6% and
28.9% of subjects in the active treatment groups had events
with Class 1 (0.5 unit) increases, between 6.3% and 10.7%
with Class 2 (1.0 unit) increases, and between 2.6% and
5.9% with Class 3 (1.5 units) increases (Table 3). As shown
in Table 1, Class 1 (0.5 unit) increases in NO, C, and/or P
scores in up to 52 weeks of treatment showed statistically
significant differences for MF vs placebo and F vs placebo
(P < 0.05). However, this finding needs to be placed in light
of the fact placebo subjects were only scheduled for 26
weeks of treatment compared to 52 weeks for the active
treatments.
Pairwise comparisons of LOCS III events in the treatment
groups showed small differences between active treat-
ments and placebo, none of which reached the threshold of
statistical significance (p  0.054 across weeks 26 and 52).
At week 26 (Table 4), differences between active treat-
ments and placebo for Class 1 events ranged from 1.1
(95% CI 7.0, 4.8) to 3.1 (95% CI 8.9, 2.7). For Class 2
events at week 26, the difference between active treat-
ments and placebo ranged from 1.4 (95% CI 5.0, 2.1) to
2.6 (95% CI 6.2, 0.6. The difference between active
treatments and placebo for Class 3 events ranged from
1.0 (95% CI 3.4, 1.2) to 1.3 (95% CI 3.7, 0.6). The
difference between corticosteroid treatment groups and
formoterol at week 26 ranged from 1.2 (95% CI e4.5, 6.9) to
0.8 (95% CI e6.4, 4.8) for Class 1 events, from 0.1 (95% CI
e3.2, 3.4) to 1.2 (95% CI e4.4, 1.9) for Class 2 events, and
from 0.3 (1.6, 2.3) to 0.0 (95% CI e1.9, 1.7) for Class 3
events.ID, twice daily; COPD, chronic obstructive pulmonary disease;
red dose inhaler; MF, mometasone furoate.
Table 1 Analysis of LOCS III grade increases after exposure to COPD and asthma study treatments for up to 52 weeks.
Treatments n Class 1a
changes
N (%)
Class 2a
changes
N (%)
Class 3a
changes
N (%)
Patient-years of exposureb
Pooled COPD studies
MF/F 200/10 mg BID 401 98 (24.4) 23 (5.7) 9 (2.2) 314.7e337.3
MF/F 400/10 mg BID 393 98 (24.9) 24 (6.1) 9 (2.3) 309.2e323.5
MF 400 mg BID 406 108 (26.6)* 38 (9.4) 18 (4.4) 310.2e327.7
F 10 mg BID 392 104 (26.5)* 31 (7.9) 12 (3.1) 310.3e327.8
Placebo BID 364 72 (19.8) 26 (7.1) 11 (3.0) 191.1e191.7
Asthma study
MF/F 200/10 mg BID 135 27 (20.0) 6 (4.4) 1 (0.7) 128.1e132.1
MF/F 400/10 mg BID 120 33 (27.5) 5 (4.2) 3 (2.5) 108.4e114.4
FP/S 250/50 mg BID 65 18 (27.7) 4 (6.2) 0 (0.0) 58.6e62.9
FP/S 500/50 mg BID 61 13 (21.3) 1 (1.6) 1 (1.6) 56.3e57.8
*P < 0.05 vs placebo; based on the Meittinen and Nurminen (MN) method. Placebo subjects were only scheduled for 26 weeks of
treatment compared to 52 weeks for the active treatments.
BID, twice daily; COPD, chronic obstructive pulmonary disease; F, formoterol; FP, fluticasone propionate; LOCS, lens opacity classifi-
cation system; MF, mometasone furoate; S, salmeterol.
a Class 1, 2, and 3 changes are LOCS III grade increases of 0.5, 1.0, and 1.5 units, respectively.
b Exposure across all grades of LOCS III increase for all randomized subjects treated for up to 52 weeks. For the pooled COPD studies,
the patient-years of exposure for Class 1, 2, and 3 increases in each treatment group are shown in Fig. 1.
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ever, since the formoterol group did not use a corticoste-
roid, this treatment was an acceptable surrogate for
placebo. At week 52 (Table 5), the difference between
steroid treatment groups and formoterol for Class 1 events
ranged from 0.7 (95% CI 8.3, 6.8) to 2.3 (95% CI 9.8,
5.3). For Class 2 events at week 52, differences ranged from
1.7 (95% CI 3.4, 6.9) to 2.8 (95% CI 7.4, 1.8). For Class 3
events at week 52, differences ranged from 2.0 (1.8, 5.9)
to 1.4 (95% CI 4.7, 1.8).
LOCS III scores in asthma
As shown in Table 1, the MF/F groups had more than twice
as many subjects as the FP/S or active-control groups.
Similar to the COPD studies, pairwise comparisons of LOCS
III events in the treatment groups showed relatively small
differences between treatments. At week 26, treatment
differences ranged from 11.0 to 9.3 for Class 1 events, 8.5
to 6.5 for Class 2 events, and 2.0 to 2.0 for Class 3
events. At week 52, treatment differences ranged from 6.5
to 13.4 for Class 1 events. Week 52 treatment differencesTable 2 Subjects with class 1, class 2, or class 3 LOCS III event
LOCS III class changes MF/F 200/10 mg BID
(n Z 349)
MF/F 400/
(n Z 330)
1 Increases 0.5, n (%) 61 (17.5) 51 (15.5)
2 Increases 1.0, n (%) 15 (4.3) 11 (3.3)
3 Increases 1.5, n (%) 4 (1.1) 4 (1.2)
See Table 4 for statistical comparisons between groups through week
BID, twice daily; COPD, chronic obstructive pulmonary disease; F, form
furoate.ranged from 2.1 to 0.2 for Class 2 events, and from 0.9 to
1.8 for Class 3 events. None of the Class 1 or 2 event
treatment differences was statistically significant.Discussion
These studies are noteworthy because they compare ef-
fects of MF/F with those of placebo and formoterol, which
are not expected to be associated with lenticular effects,
and also with FP/S, which is another ICS/LABA combination.
In the pooled COPD studies (Table 1), the prevalence of all 3
classes of lenticular change was slightly higher in the F
group than it was in either MF/F group over up to 52 weeks
of treatment. Lenticular shifts were also generally small
and nonsignificant in the asthma study. The incidence of
lenticular change in Class 1 and Class 2 was higher in the
FP/S 250/50 group than it was in any other group, including
the FP/S 500/50 group (Table 1).
In the COPD studies, 6.0% of the placebo group had LOCS
III changes 1.0 at end of 26 weeks, which is important and
showed that the system picked up an age-related change.s through Week 26 in the pooled COPD studies.
10 mg BID MF
400 mg BID
(n Z 346)
F
10 mg
BID
(n Z 332)
Placebo BID
(n Z 318)
57 (16.5) 54 (16.3) 59 (18.6)
16 (4.6) 15 (4.5) 19 (6.0)
3 (0.9) 3 (0.9) 7 (2.2)
26 in the pooled COPD studies.
oterol; LOCS, lens opacity classification system; MF, mometasone
Table 3 Subjects with class 1, class 2, or class 3 LOCS III events between week 26 and week 52 in the pooled COPD studies.
LOCS III class changes MF/F
200/10 mg BID
(n Z 271)
MF/F
400/10 mg BID
(n Z 267)
MF
400 mg BID
(n Z 270)
F
10 mg BID
(n Z 277)
1 Increases 0.5, n (%) 72 (26.6) 71 (26.6) 76 (28.1) 80 (28.9)
2 Increases 1.0, n (%) 17 (6.3) 17 (6.4) 29 (10.7) 25 (9.0)
3 Increases 1.5, n (%) 7 (2.6) 7 (2.6) 16 (5.9) 11 (4.0)
See Table 5 for statistical comparisons between groups between week 26 and week 52 in the pooled COPD studies.
BID, twice daily; COPD, chronic obstructive pulmonary disease; F, formoterol; LOCS, lens opacity classification system; MF, mometasone
furoate.
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changes observed in the placebo groups within the first 26
weeks of treatment, the data suggest that an active
treatment effect was not present and the changes were not
clinically meaningful. The latter is further supported by the
sample sizes which are considered large enough to detect
differences like those observed.
TheCOPD-study populationswere larger than the asthma-
study population, and they included a placebo control group
for the first 26weeks. It is important to note that the placebo
group discontinued at week 26, and that patient selection
was blinded for extension to week 52. Therefore, we believe
that at week 52, the formoterol group is an acceptable sur-
rogate for placebo. It is also important to note that LOCS III
was performed on a pre-determined schedule (screening,
week 26, and week 52), meaning that events could have
occurred prior to the actual evaluation but were not recor-
ded until the evaluation took place. Scheduling of placebo
treatment to end at week 26, compared with 75% of active
treatments continuing to week 52, means an exposure
adjustment to the analysis would overestimate the exposure
prior to the event. Therefore, raw percentages are reported
for each evaluation.Table 4 Differences in LOCS III event rates through week 26 in
Pair-wi
Differe
Class 1: 0.5 unit
MF/F 200/10 mg BID e Placebo BID 1.1 (
MF/F 400/10 mg BID e Placebo BID 3.1 (
MF MDI 400 mg BID e Placebo BID 2.1 (
F 10 mg BID e Placebo BID 2.3 (
Class 2: 1.0 unit
MF/F 200/10 mg BID e Placebo BID 1.7 (
MF/F 400/10 mg BID e Placebo BID 2.6 (
MF MDI 400 mg BID e Placebo BID 1.4 (
F 10 mg BID e Placebo BID 1.5 (
Class 3: 1.5 unit
MF/F 200/10 mg BID e Placebo BID 1.1 (
MF/F 400/10 mg BID e Placebo BID 1.0 (
MF MDI 400 mg BID e Placebo BID 1.3 (
F 10 mg BID e Placebo BID 1.3 (
BID, twice daily; COPD, chronic obstructive pulmonary disease; F, fo
dose inhaler; MF, mometasone furoate.
a Confidence Intervals and p-values are based on the Meittinen andThe rate of events was higher in the COPD studies than it
was in the asthma study. Of course it is possible that this
difference may be a function of population sizes and the
type of statistical model used for the analyses. Further
study may be needed to confirm the findings presented
here. In addition, age-adjusted analyses remove the impact
of age differences in LOCS III results, but the analyses
conducted here are limited in that they did not include age
adjustment. It is also possible that higher event rates in the
COPD studies are a product of overall cataract risk factors.
The fact that patients in the COPD studies were older than
patients in the asthma study, and that the COPD studies had
higher proportions of smokers, suggests these factors may
have influenced the LOCS III outcomes. However, age and
smoking are only two of the background risk factors for
cataract. Case-control and population-based studies have
found cataract risk to be higher in women than in men, and
to be higher in patients with brown irises, as well as in
conditions including diabetes, smoking, myopia, high
exposure to sunlight, glaucoma, chronic bronchitis, and
asthma [14e16].
An important difference between the MF/F studies and
the CIC vs BDP study mentioned previously is that the twothe pooled COPD studies.
se comparisons of event rates
nce in event rates (95% CI)a Two-sided
MN P-valuesa
7.0, 4.8) 0.718
8.9, 2.7) 0.294
7.9, 3.7) 0.481
8.2, 3.6) 0.442
5.3, 1.7) 0.326
6.2, 0.6) 0.110
5.0, 2.1) 0.437
5.1, 2.0) 0.405
3.5, 1.0) 0.286
3.4, 1.2) 0.330
3.7, 0.6) 0.159
3.7, 0.7) 0.179
rmoterol; LOCS, lens opacity classification system; MDI, metered
Nurminen (MN) method.
Table 5 Differences in LOCS III event rates between week 26 and week 52 in the pooled COPD studies.
Pair-wise comparisons of event rates
Difference in event rates (95% CI)a Two-sided MN P-valuesa
Class 1: 0.5 unit
MF/F 200/10 mg BID  MF/F 400/10 mg BID 0.0 (7.5, 7.4) 0.995
MF/F 200/10 mg BID e MF MDI 400 mg BID BIDBBIDBIDBID 1.6 (9.1, 5.9) 0.681
MF/F 200/10 mg BID e F 10 mg BID 2.3 (9.8, 5.2) 0.546
MF/F 400/10 mg BID e MF MDI 400 mg BID BIDBBIDBIDBID 1.6 (9.1, 6.0) 0.686
MF/F 400/10 mg BID e F 10 mg BID 2.3 (9.8, 5.3) 0.552
MF MDI 400 mg BID e F 10 mg BID 0.7 (8.3, 6.8) 0.850
Class 2: 1.0 unit
MF/F 200/10 mg BID  MF/F 400/10 mg BID 0.1 (4.4, 4.2) 0.964
MF/F 200/10 mg BID e MF MDI 400 mg BID BIDBBIDBIDBID 4.5 (9.4, 0.2) 0.063
MF/F 200/10 mg BID e F 10 mg BID 2.8 (7.4, 1.8) 0.226
MF/F 400/10 mg BID e MF MDI 400 mg BID BIDBBIDBIDBID 4.4 (9.3, 0.4) 0.070
MF/F 400/10 mg BID e F 10 mg BID 2.7 (7.3, 1.9) 0.246
MF MDI 400 mg BID e F 10 mg BID 1.7 (3.4, 6.9) 0.502
Class 3: 1.5 unit
MF/F 200/10 mg BID  MF/F 400/10 mg BID 0.0 (3.1, 2.9) 0.978
MF/F 200/10 mg BID e MF MDI 400 mg BID BIDBBIDBIDBID 3.3 (7.1, 0.1) 0.054
MF/F 200/10 mg BID e F 10 mg BID 1.4 (4.7, 1.8) 0.362
MF/F 400/10 mg BID e MF MDI 400 mg BID BIDBBIDBIDBID 3.3 (7.1, 0.1) 0.059
MF/F 400/10 mg BID e F 10 mg BID 1.3 (4.7, 1.8) 0.379
MF MDI 400 mg BID e F 10 mg BID 2.0 (1.8, 5.9) 0.292
BID, twice daily; COPD, chronic obstructive pulmonary disease; F, formoterol; LOCS, lens opacity classification system; MDI, metered
dose inhaler; MF, mometasone furoate.
a Confidence Intervals and p-values are based on the Meittinen and Nurminen (MN) method.
Appraisal of lens opacity in patients with COPD or asthma 1361MF/F COPD studies have older populations, which would
increase the age-related risk of cataract. The CIC vs BDP
study had patients 18e80 years of age (mean Z 43 y) [9],
whereas the MF/F COPD studies had patients 4089 years
of age (meanZ 60 y [17]). Another difference between the
MF/F studies and the CIC vs BDP study is that the latter
included grading of Class II sustained, which is occurrence
of a Class 2 shift at any time point followed by a Class 1 shift
in the same eye at a subsequent visit. The CIC vs BDP study
also reported negative class shifts in LOCS III scores [9],
which may occur due to low thresholds to define shifts, as
well as grader variability.
The protocols for the MF/F studies mandated that LOCS III
grading at all visits was to be done by the same ophthal-
mologist, which ameliorates grader variability. Ophthal-
mologists performed slit lamp examinations with dilation,
but the critical issue is whether or not the pupillary dilation
was maximal. Maximal dilation, which was not stipulated in
theMF/F study protocols, assures that variations in pupil size
from visit to visit do not affect the LOCS III grading. For
example, if a pupil is smaller at follow-up than at baseline,
the LOCS III C and P grading might be less than the baseline
grade even if there was no actual change in the extent of C or
P opacification. This would be due to the fact that the
smaller pupil sizes allowed visualization of less of the C or P
opacities. The effect of a non-maximally dilated pupil on the
LOCS III grade would be to yield lower C and perhaps P
grades. This would be evident in the LOCS III data as an
apparent improvement in the severity of the opacity. It
would not havemuch of an effect on the NO and NC grades. It
is likely that many of the subjects in fact ended up with
maximally dilated pupils at the time of the LOCS III grading,since many people dilate rapidly and achieve maximal dila-
tation with a sub-maximal dose of mydriatic.
Exposure to corticosteroids before treatment in cataract
studies of ICS with or without LABAs is certainly an important
factor to address in study design and to consider in the
interpretation of results. Some children with renal trans-
plantswho received prednisone got cataracts; these stay and
don’t decrease, but can worsen if they receive a drug that
has lens effects [18]. A caseecontrol study in the United
Kingdom with a mean observation period of 4.5 years found
an increased risk of cataract associated with both COPD
(odds ratio [OR] Z 1.49) and asthma (OR Z 1.52). These
increases in risk were attributed to previous ICS or oral
corticosteroid therapy [19]. In addition, that study found a
dose-related increase in risk of cataracts in patients who had
ever used an ICS. The OR for cataract ranged from 0.99 in
low-dose ICS users to 1.69 in very high-dose ICS users [19].
Since assessments were only performed after a
maximum of 52 weeks of exposure to the various treat-
ments, the possibility of effects of MF/F or MF on lens
opacity after more prolonged periods of ICS exposure
cannot be excluded. No clinically relevant trends were
observed in the LOCS III assessment of lenticular shifts
during treatment with MF/F. In these one-year trials, MF/F
effects on lens opacity were not observed.Conflict of interest statement
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